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SCIENTIFIC OPINION 
Scientific Opinion on an alternative method for the hygienic treatment of 
bovine colostrum through a series of filtration steps
1
 
EFSA Panel on Biological Hazards (BIOHAZ)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
An alternative method to the HTST treatment (High Temperature Short Time pasteurisation at 72 °C for at least 
15 seconds or equivalent pasteurisation effect achieving a negative reaction to a phosphatase test), approved for 
the treatment of bovine colostrum (Category 3 material), was assessed. The purpose of the alternative method, 
based on a series of filtration steps, is the production of Colostrinov, a product whose main ingredient is bovine 
colostrum, to be used for foal nutrition. Since the filtration techniques used are known to eliminate particles of 
the size of bacteria, fungi and protozoa from liquids, it is reasonable to assume that the microfiltration process 
reduces these contaminants to a level at least equivalent to the treatment required by the legislation. Owing to 
their small size, viruses are not retained by the mechanical effect of the filters but they may be retained by 
physico-chemical interactions with the surface of the filter, depending on the surface properties of the viruses 
and those of the filter, as well as on the properties of the surrounding liquid. From the information provided by 
the applicant, it cannot be concluded whether or not the microfiltration process reduces the relevant viral 
contaminants to a level at least equivalent to a single HTST treatment as required by the legislation. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the Permanent Representation of France to the European Union (EU) 
(competent authority) on behalf of the French company IMV-Technologies, the European Food Safety 
Authority (EFSA) Scientific Panel on Biological Hazards (BIOHAZ Panel) was asked to deliver a 
scientific opinion on an alternative method for hygienic treatment of bovine colostrum.  
Raw bovine colostrum (first milk after parturition) (Category 3 material) is considered to be raw milk 
as per Article 10(h) of Regulation (EC) 1069/2009, the Animal By-product Regulation (ABP). 
According to Point 6.3 of Section 4, Part I.B, Chapter II, Annex X of  Regulation (EC) 142/2011, 
colostrum or colostrum products must have undergone a single HTST treatment (HTST = High 
Temperature Short Time pasteurisation at 72 °C for at least 15 seconds or equivalent pasteurisation 
effect achieving a negative reaction to a phosphatase test). 
Under point 5 of Article 20 of Regulation 1069/2009 it is specified that EFSA shall assess whether the 
alternative method submitted ensures that risks to public or animal health are: a) controlled in a 
manner which prevents their proliferation before disposal in accordance with this Regulation or the 
implementing measures thereof; or b) reduced to a degree which is at least equivalent, for the relevant 
category of animal by-products, to the processing methods laid down pursuant to point (b) of the first 
subparagraph of Article 15(1). 
The alternative method is based on a series of filtration steps for the production of Colostrinov, a 
product whose main ingredient is bovine colostrum. The intended use of the product, rich in 
immunoglobulin (Ig)G, is foal nutrition. Following a confidentiality claim, the description of the 
process has been edited.  
The BIOHAZ Panel considered a list of main hazards potentially present in bovine colostrum: 
pathogenic and non-pathogenic bacteria, pathogenic viruses, pathogenic fungi and pathogenic 
protozoa. Since the filtration techniques used are known to eliminate particles of the size of bacteria, 
fungi and protozoa from liquids, it is reasonable to assume that the microfiltration process reduces 
these contaminants to a level at least equivalent to the treatment required by the legislation. 
However, no information is provided in the application on the potential reduction in pathogenic 
viruses in colostrum after applying the alternative method. The data provided in the literature attached 
to the application refer only to bacteriophages. The applicant did not perform an experiment with 
colostrum containing, or spiked with, appropriate indicators of the relevant pathogenic viruses. 
Owing to their small size, viruses are not retained by the mechanical effect of the filters but they may 
be retained by physico-chemical interactions with the surface of the filter, depending on the surface 
properties of the viruses and those of the filter, as well as on the properties of the surrounding liquid. 
Therefore, a description of the characteristics of the filters used for the microfiltration process is 
essential. 
From the information provided by the applicant, it cannot be concluded whether or not the 
microfiltration process reduces the relevant viral contaminants to a level at least equivalent to a single 
HTST treatment as required by the legislation. Although a detailed Hazard Analysis and Critical 
Control Points (HACCP) Plan was provided, some improvements are necessary. In particular, a full 
list of hazards should be provided and microfiltration should be identified as a Critical Control Point 
(CCP) for virus reduction. In this context, the characteristics of the micro-filters should be clearly 
specified in the description of the process. The control of the filtration process and maintenance of the 
equipment are essential for the efficacy of any method based on filtration. 
The efficacy of the alternative method should be validated with colostrum artificially contaminated 
with suitable test-viruses, selected according to their size and surface properties, and not to their 
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thermal resistance. Only test-strains should be used for which approved quantitative laboratory 
methods are available comparable to those described for testing disinfectants.  
The cold chain, as described in the application, should be maintained at all times in order to ensure the 
safety of the product. Systems should be in place to ensure the safe disposal of wastewater. 
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BACKGROUND AS PROVIDED BY THE FRENCH COMPETENT AUTHORITY 
On 01 October 2014, The European Food Safety Authority (EFSA) received from the Permanent 
Representation of France to the EU (competent authority) the application (mandate and technical 
dossier) under Regulation (EC) No 1069/2009
4
 and Regulation (EU) No 142/2011,
5
 referring to the 
request for evaluation of an alternative method for hygienic treatment of colostrum, submitted by 
IMV-Technologies. 
The application dossier includes a number of supporting documents which have also been listed in the 
enclosed Index.   
TERMS OF REFERENCE AS PROVIDED BY THE FRENCH COMPETENT AUTHORITY 
The French competent authority asked EFSA to assess an alternative method for hygienic treatment of 
bovine colostrum (Category 3 material) via microfiltration, intended to be used for foal nutrition, 
according to Article 20 of Regulation (EC) 1069/2009 and Annex VII of Regulation (EU) 142/2011. 
In point 5 of Article 20, it is specified that EFSA shall assess whether the method submitted ensures 
that risks to public or animal health are: 
a) controlled in a manner which prevents their proliferation before disposal in accordance with 
this Regulation or the implementing measures thereof; or 
b) reduced to a degree which is at least equivalent, for the relevant category of animal by-
products, to the processing methods laid down pursuant to point (b) of the first subparagraph 
of Article 15(1). 
The proposed method is an alternative to the approved one.  According to Point 6.3 of Section 4, Part 
I.B, Chapter II, Annex X of  Regulation (EC) 142/2011, colostrum or colostrum products must have 
undergone a single HTST treatment (HTST = High Temperature Short Time pasteurisation at 72 °C 
for at least 15 seconds or equivalent pasteurisation effect achieving a negative reaction to a 
phosphatase test). 
 
                                                     
4  Regulation (EC) No 1069/2009 of the European Parliament and of the Council of 21 October 2009 laying down health 
rules as regards animal by-products and derived products not intended for human consumption and repealing Regulation 
(EC) No 1774/2002 (Animal by-products Regulation), OJ L 300, 14.11.2009, p. 1–33, as last amended. 
5  Commission Regulation (EU) No 142/2011 of 25 February 2011 implementing Regulation (EC) No 1069/2009 of the 
European Parliament and of the Council laying down health rules as regards animal by-products and derived products not 
intended for human consumption and implementing Council Directive 97/78/EC as regards certain samples and items 
exempt from veterinary checks at the border under that Directive, OJ L 54, 26.2.2011, p. 1–254, as last amended. 
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ASSESSMENT 
1. Introduction 
The terminology used in this assessment conforms to the ‘Statement on technical assistance on the 
format for applications for new alternative methods for animal by-products’ (EFSA BIOHAZ Panel, 
2010). The assessment considers only biological hazards. Other hazards (e.g. physical, chemical or 
radiological) are not considered. 
The assessment of the application received was performed taking into account the criteria laid down in 
Article 20, point 5 of Regulation (EC) 1069/2009 (the Animal By-Products (ABP) Regulation). The 
purpose of the alternative method is the production of Colostrinov, a product whose main ingredient is 
bovine colostrum, to be used for foal nutrition. 
2. Full description of the process 
According to Annex VII to Regulation (EU) 142/2011, the applicant is required to provide a full 
description of the process to be assessed.
6
  
The following text, along with Figure 1, summarises the information provided. 
2.1. Collection 
The animals that contribute to the production of colostrum are subjected to the same requirements as 
those that produce milk for human consumption. The colostrum is collected by the producers into 
clean, disinfected, milking machine pots dedicated to this use. The pots are packaged immediately in 
disposable, double-lined, food-grade plastic bags and then frozen at – 18 °C in freezers made available 
to the producers. A label containing a producer-specific bar code is placed on each bag. 
The colostrum is transferred frozen taking the necessary precautions either to a processing plant for 
dairy products (company 1) licensed under Regulation (EC) 853/2004
7
 where it is stored in a freezer 
(at − 18 °C) dedicated to colostrum harvesting, or to a dedicated freezer in a cold store company 
(company 2). 
2.2. Thawing and skimming 
The process of production starts with the raw material, i.e. frozen bovine colostrum at − 18 °C. 
According to the application, frozen colostrum is quickly thawed in specifically designed equipment in 
less than 60 minutes; the colostrum temperature is increased from – 18 °C to 15 °C. However, there is 
an inconsistency between the application dossier and the Hazard Analysis and Critical Control Points 
(HACCP) plan in relation to the thawing process. This is further discussed in section 6 (HACCP plan) 
of this Scientific Opinion.  
From the colostrum thawing stage onwards, a representative sample is taken from all of the 
unprocessed colostrum used in order to detect the presence of salmonellae. 
The colostrum is then skimmed at 38 °C in a skimmer dedicated to this purpose and the cream is then 
disposed of in accordance with the ABP Regulation. 
2.3. Filtrations 
The skimmed colostrum is transferred into the microfiltration operating unit (0.1 µm) feeding tank, 
which is located in another room at positive pressure. The permeate, which is rich in immunoglobulin 
(Ig)G, is transferred to a frontal filtration unit (0.45 µm) and then to the ultrafiltration feeder tank. The 
                                                     
6  This section has been edited following a confidentiality claim made by the applicant. 
7  Regulation (EC) No 853/2004 of the European Parliament and of the Council of 29 April 2004 laying down specific 
hygiene rules for the hygiene of foodstuffs. OJ L 139, 30.4.2004, p. 55–151. 
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ultrafiltration retentate remains in the ultrafiltration unit until its refractive index reaches 25 %. The 
final product goes through another filtration (0.22 µm) at a later stage (see Section 2.5).  
There is no description in the application on the characteristics of the filters used for the 
microfiltration and ultrafiltration. There are no details either on the protocol for maintenance and 
verification of the filters except the verification of the 0.45 µm filter integrity by measurement of the 
bubble point, the visual monitoring of absence of leakage and the verification of the integrity of the 
filters before and after the production process. The corrective action is the replacement with a new 
filter and the destruction of the deteriorated one. 
According to the HACCP Plan, cleaning and disinfection of dedicated equipment for production of 
colostrum, namely, filtration units, filters, circuits and trays, is done as a preventative measure to avoid 
microbiological contamination. The microfiltration filter is steam sterilised and the filter is autoclaved 
prior to re-use. In order to avoid microbiological and chemical contamination, cleaning-in-place is 
done including rinsing and use of cleaning agents and disinfectants accredited for foodstuff use. 
2.4. Cooling 
When the refractive index of the ultrafiltration retentate reaches 25 %, a valve opens automatically to 
release it into a continuously-mixed cooling tank where it reaches temperatures between 2 °C and 
10 °C. The tank is sealed and stored in a cold room (4 °C) until it is transported for one hour to the 
next site (IMV-Technologies). There is no information on the length of time that the colostrum is kept 
in the cold room or on the transport temperature. 
2.5. Freezing 
As soon as it is received at IMV-Technologies, the tank is stored in a cold room (4 °C) until its 
contents are used, less than 48 hours after receipt. The concentrated serocolostrum is then filtered 
through 0.22 µm filters before aliquots are dispensed into disposable bags which are placed on 
stainless steel trays. There are no details of the material with which the disposable bags are 
manufactured. The serocolostrum is then frozen. All of these procedures are carried out in an ISO8-
compliant room. 
2.6. Freeze-drying 
The frozen bags are transported to a freeze-drying company (company 3) where they are transferred 
immediately to large bags and then to freezers (at − 18 °C) equipped with temperature probes and 
alarms. On the day of freeze-drying, the bags are weighed, opened and positioned on freeze-drying 
shelves, which  have been previously cleaned and disinfected. No further details are provided on these 
procedures.  
After a 72-hour cycle, the lyophilisate (also called the dry extract) is removed from the freeze-dryer 
and packaged in farming-foodstuff certified grade disposable polyethylene bags. These packages, 
which each weigh 5 kg, are then packaged in a large (double-lined) bag. All of these procedures are 
carried out in an ISO8-compliant room. The 5 kg packs are sent to IMV-Technologies within 48 hours 
of production. 
2.7. Packaging of the commercial product 
The 5 kg packs are stored in a cold room at 4 °C as soon as they are received. A 174 g mass of 
lyophilisate followed by 90 g of powdered milk are added into a new 1 000 mL polyethylene 
terephthalate (PET) bottle. The bottle is then closed with the PET top. All of these procedures are 
carried out in an ISO8-compliant room. Each bottle is fitted with a feeding teat for marketing. The 
commercial product must be stored in a cool and dry place and away from light (at temperature not 
exceeding 30 °C) for a maximum of one year after packaging. 
‘Microfiltration’ application 
 
EFSA Journal 2015;13(6):4139 8 
 
Figure 1:  Summary diagram of the production process as proposed by the IMV-Technologies 
excluding the confidential steps 
3. Full description of the material to be treated 
Raw bovine colostrum (first milk after parturition) (Category 3 material) is considered to be raw milk 
as per Article 10(h) of Regulation (EC) 1069/2009 (the ABP Regulation). Colostrum means ‘the fluid 
secreted by the mammary glands of milk-producing animals up to three to five days post parturition 
that is rich in antibodies and minerals, and precedes the production of raw milk’, according to 
Regulation (EC) 853/2004, Annex III, Section IX, as amended. The health requirements for raw milk 
and colostrum production are the same, as per Chapter I, Section IX, Annex III of Regulation (EC) 
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853/2004, as amended by Regulation (EC) 1662/2006.
8
 Milk, milk-based products, milk-derived 
products, colostrum and colostrum products require different certificates for import into the European 
Union (EU) from third countries (non-EU members), as stated in the Regulation (EC) 142/2011
9
 
Annex XV, Chapters 2 (A) and 2 (B).  
According to point 6 Section 4 Part I.B, Chapter II, Annex X of Regulation (EC) 142/2011, colostrum 
and colostrum products must:  
6.1 be obtained from bovine animals kept on a holding on which all bovine herds are recognised 
Officially Tuberculosis-Free, Officially Brucellosis-Free and Officially Enzootic-Bovine-
Leukosis free as defined in Article 2(2)((d), (f) and (j)) of Directive 64/432/EEC;
10
 
6.2 have been produced at least 21 days before shipping (during that period no case of foot-and-
mouth disease must have been detected in the Member State of origin); 
6.3 have undergone a single HTST treatment (high-temperature short-time pasteurisation at 72 °C 
for at least 15 seconds or equivalent pasteurisation effect achieving a negative reaction to a 
phosphatase test); 
6.4 comply with the requirements set out in point 4 of Part I.B:  
4.1 after completion of the processing, every precaution must be taken to prevent 
contamination of the products; 
4.2  the final product must be labelled so as to indicate that it contains Category 3 material 
and is not intended for human consumption and it must be: a) packed in new containers; 
or b) transported in bulk in containers or other means of transport that before use were 
thoroughly cleansed and disinfected. 
With regards to the assessment, Article 20 of Reg. 1069/2009 specifies that the method submitted for 
approval must reduce the public or animal health risks to a degree at least equivalent, for the relevant 
category of animal by-products, to the processing methods laid down pursuant to point (b) of the first 
subparagraph of Article 15(1). The laid-down processing method for colostrum is the HTST as 
described above in point 6.3. 
4. Hazard identification 
A comprehensive list of pathogens that could be present in colostrum was not provided by the 
applicant. The EFSA Panel on Biological Hazards (BIOHAZ Panel) considered the list of main 
hazards potentially present in bovine colostrum (those mentioned by the applicant are highlighted with 
an asterisk) (Peterson, 1965; Kawakami et al., 1966; Richardson, 1970; Ménard et al., 1983; Timoney 
et al., 1988; Watts, 1988; Lorenz et al., 1998; Waage et al., 1999; Pardo et al., 2001; Mukherjee et al., 
2004; Izumi et al., 2006; Biesenkamp-Uhe et al., 2007; Barlow et al., 2008; Cervinkova et al., 2013; 
EFSA BIOHAZ Panel, 2015). 
The hazards included in the list have been compiled from those reported in the literature as excreted in 
bovine milk, regardless of their excretion in equine milk or their pathogenicity for equines. It was 
                                                     
8  Commission Regulation (EC) No 1662/2006 of 6 November 2006 amending Regulation (EC) No 853/2004 of the 
European Parliament and of the Council laying down specific hygiene rules for food of animal origin. OJ L 320, 
18.11.2006, p. 1–10. 
9  Commission Regulation (EU) No 142/2011 of 25 February 2011 implementing Regulation (EC) No 1069/2009 of the 
European Parliament and of the Council laying down health rules as regards animal by-products and derived products not 
intended for human consumption and implementing Council Directive 97/78/EC as regards certain samples and items 
exempt from veterinary checks at the border under that Directive. OJ L 54, 26.2.2011, p. 1–254. 
10  Council Directive 64/432/EEC of 26 June 1964 on animal health problems affecting intra-Community trade in bovine 
animals and swine. OJ L 121, 29.7.1964, p. 1977–2012. 
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decided not to include equine pathogens since the reduction of the pathogen load in the raw material as 
evidence of the effectiveness of the method can only be assessed with pathogens present in bovine 
colostrum. Moreover, while the intended use of Colostrinov is foal nutrition, its administration to other 
species susceptible to pathogens included in the list cannot be excluded. 
4.1. Bacteria 
Bacterial pathogens, for example: 
 Arcanobacterium pyogenes 
 Bacillus cereus 
 Brucella abortus 
 Campylobacter spp. (thermophilic) 
 Chlamydophila abortus 
 Clostridium perfringens 
 Corynebacterium spp. 
 Coxiella burnetii 
 Histophilus somni 
 Klebsiella spp. 
 Listeria monocytogenes* 
 Mycoplasma bovis 
 Mycobacterium bovis 
 Mycobacterium spp. (Atypical mycobacteria e.g. M. phlei, M. fortuitum, M. smegmatis, 
M. avium, M. chelonae) 
 Salmonella spp.* (non-typhoid) 
 Shigatoxin-producing Escherichia coli (STEC)* 
 Staphylococcus aureus* 
 Streptococcus agalactiae 
 Streptococcus equi subsp. zooepidemicus 
 Yersinia enterocolitica 
 Yersinia pseudotuberculosis 
Besides pathogenic bacteria, a variety of non-pathogenic bacteria may cause spoilage of the final 
products under certain conditions, or be used as hygiene indicators. These include: 
 coliforms* 
 Enterobacteriaceae 
 Pseudomonas spp. 
 Streptococcus spp. 
 Bacillus spp. 
 Clostridium spp. 
4.2. Pathogenic viruses 
 Bovine enterovirus  
 Bovine herpesvirus 1 
 Bovine herpesvirus 4 
 Bovine immunodeficiency virus  
 Bovine leukemia virus 
 Bovine morbillivirus 
 Bovine papillomavirus 
 Foot-and-mouth disease virus 
 Parainfluenza 3 virus 
 Parapoxvirus bovis 
 Tick-borne encephalitis virus  
‘Microfiltration’ application 
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 Vesicular stomatitis virus 
 Bovine viral diarrhoea virus 
The viruses in the list above are those described in the literature as being excreted by the mammary 
gland of bovines in milk (Straub and Kielwein, 1965; Timoney et al., 1988; Watts, 1988;  Wellenberg 
et al., 2002; Jost and Billington, 2005; Haskell, 2011; Franco et al., 2013; EFSA BIOHAZ Panel, 
2015). Of those included in the list, the Tick-borne encephalitis virus (Sellon and Long, 2007; 
McLachlan and Dubodi, 2011), the Vesicular stomatitis virus (Sellon and Long, 2007; McLachlan and 
Dubodi, 2011) and the Bovine papillomavirus (Bocaneti et al., 2014) are known to be pathogenic for 
equines. It cannot be ruled out that additional viruses may be found in colostrum during the 
septicaemic phase of an infection, due to the large content number of cells and large amount of blood-
derived proteins in colostrum. Besides pathogenic viruses in the colostrum itself, a variety of viruses 
of faecal origin may contaminate the final product under certain conditions. Therefore, a secondary 
risk may be considered, e.g. due to the presence of: 
 Bovine rotavirus 
 Bovine parvovirus 
 Bovine coronavirus 
4.3. Pathogenic fungi 
 Candida albicans 
 Prototheca zopfii 
A variety of non-pathogenic fungi may cause spoilage of the final products under certain conditions. 
4.4. Pathogenic protozoa 
 Cryptosporidium parvum 
 Toxoplasma gondii 
Viruses and fungi were not considered by the applicant in its experimental assessment of risk 
reduction and this is one of the problems of the application. Only some bacteriophages are mentioned 
as test organisms in the literature review attached to the application.  
Further details on potential hazards present in bovine raw milk are provided in the EFSA’s scientific 
opinion on the public health risks related to the consumption of raw drinking milk (EFSA BIOHAZ 
Panel, 2015).  
5. Level of risk reduction 
5.1. Pathogenic bacteria  
The type of filters used in the process can reduce the level of bacterial pathogens to at least the same 
extent as the HTST pasteurisation process, as required in Regulation (EC) 142/2011, Annex X, 
Chapter II, Section 4 Part I.B, point 6, whereby colostrum and colostrum products must have 
undergone a single HTST treatment. 
The applicant carried out microbiological tests on five lots of finished serocolostrum product. The 
results for the five lots of product showed a reduction in total mesophilic counts from 1.2 × 10
7
 to 
below the detection level (less than 100 CFU/mL) after microfiltration. The absence of Salmonella in 
25 g of sample was reported in both the raw material and the end product. No experiments were 
performed with product spiked with indicator microorganisms in order to determine the actual level of 
reduction of a particular bacterial population. Nevertheless, since the filtration techniques used are 
known to eliminate particles of the size of bacteria from liquids, it is reasonable to assume that the 
microfiltration process reduces bacterial contaminants to a level at least equivalent to the treatment 
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required by the legislation. This equivalent reduction has been reported elsewhere (Saboya and 
Maubois, 2000, as provided by the applicant).  
5.2. Pathogenic viruses 
The applicant reports the absence of bovine viral diarrhoea and of infectious bovine rhinotracheitis in 
five lots of finished serocolostrum product and the absence of equine coronavirus and equine rotavirus 
in the final product. However, no information is provided in the application on the potential reduction 
in pathogenic viruses in colostrum after applying the alternative method. The data provided in the 
literature attached to the application refer only to bacteriophages. The applicant did not perform an 
experiment with colostrum containing, or spiked with, appropriate indicators of the relevant 
pathogenic viruses. 
Owing to their small size, viruses are not retained by the mechanical effect of the filters but they may 
be retained by physico-chemical interactions with the surface of the filter, depending on the surface 
properties of the viruses and those of the filter, as well as on the properties of the surrounding liquid. 
Therefore, a description of the characteristics of the filters used for the microfiltration process is 
essential. Data on the effectiveness of HTST treatment on virus reduction in the scientific literature is 
limited.  HTST is not adequate to eliminate foot-and-mouth disease virus (FMDV) in milk completely 
(Cunliffe et al., 1979; Tomasula and Konstance, 2004) as shown in different studies. For example, 
HTST achieved a 4 log10 reduction of FMDV in bovine milk, although it did not completely remove 
infectivity (Aly and Gaber, 2007; Tomasula et al., 2007). Similar findings were reported by Donaldson 
(1997) and Ryan et al. (2008) with a 5 log10 reduction. HTST was also found to only partially 
inactivate poliovirus type 1 (Strazynski et al., 2002). In a study in human milk, HTST pasteurisation is 
highly effective against some lipid enveloped viruses of pathogenic potential in humans, with limited 
or no inactivation observed for some non-lipid enveloped viruses (Terpstra et al., 2007). In addition, 
according to Escudero-Abarca et al. (2014), milk pasteurisation may not be stringent enough to 
eliminate Snow Mountain virus (SMV), and perhaps other prototype human norovirus (HuNoV).  
It must be kept in mind that the physico-chemical properties of bacteriophages may be different from 
those of viruses of warm-blooded animals. Even within a particular species of viruses, surface-
properties may be highly variable, and it is essential to use a conservative indicator virus or 
bacteriophage. The high organic content of colostrum is expected to interfere with the efficient 
adsorption of viruses in the filters. 
Certain steps of the manufacturing process
11
 may modify the viral load and therefore may also have an 
impact on the efficacy of the process to reduce the level of viruses. This impact could not be 
determined based on the information provided.  
From the information provided by the applicant, it cannot be concluded whether or not the 
microfiltration process reduces the relevant viral contaminants to a level at least equivalent to a single 
HTST treatment as required by the legislation.  
6. HACCP Plan 
Although a detailed HACCP Plan was provided, some improvements are necessary: 
 A comprehensive list of pathogens that could be present in bovine colostrum should have been 
provided.  
 Despite the fact that the microfiltration stage of the manufacturing process is the key and only 
process of the alternative method that, according to the applicant, should remove viruses from 
the product, no critical control point (CCP) is identified at this stage for viruses. In particular, 
the last filtration before the freezing stage uses a 0.22 µm filter that retains bacteria but not 
                                                     
11  Described in paragraphs 2 and 4 of Section 3 of Annex 6 of the application which is confidential information. 
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viruses. The filtration described in the freezing stage permits bacterial and fungal sterility but 
not viral sterility. This retention of viruses, if adequately validated, should be mentioned in the 
description of the filtration stages and added to the HACCP table, which should include details 
such as cause of failure to retain the viruses, parameters to control, preventive measures and 
monitoring and corrective actions. Equally the description of the protocols of use, 
maintenance, control of malfunctioning and lifespan of the filters should be included in the 
HACCP table.  
 The freezing stage is considered by the applicant as a CCP for microbial contamination. The 
applicant should rename the stage, or subdivide it to clearly clarify that it includes the last 
filtration and the final packaging. 
 There is an inconsistency between the application and the HACCP plan in relation to time and 
temperature of the thawing step. According to the application, frozen colostrum is quickly 
thawed in specifically designed equipment in less than 60 minutes and the colostrum 
temperature is increased from − 18 °C to 15 °C. However, the HACCP plan states that the 
bags of colostrum are placed the day before production in a cold room (at ≤ 4 °C for a 
maximum of 24 hours). On production day, the bags are rinsed with process water, weighed, 
opened, and the blocks of frozen colostrum are placed in a cabinet dedicated to this purpose. 
Clarity is required on this point.  
 Disinfectants for cleaning-in-place should be selected from those disinfectants that are used in 
the veterinary field. There is no validation of the efficacy of the disinfection procedures in 
place in the HACCP Plan. 
 The steam sterilisation of the microfiltration unit and the specification of the technical 
parameters to be kept should be mentioned in the monitoring details section of the HACCP 
table. Similarly, at the freezing stage the autoclaving of the filtration system should be 
mentioned. 
7. Risk associated with interdependent processes 
There is a detailed description of the by-products that are produced during the application of the 
alternative method. All by-products are intended to be ‘disposed of in an authorised landfill, following 
processing’, as per Regulation (EC) 1069/2009, Chapter II, Section 2, Article 14(c). However, no 
information is provided on the disposal of wastewater produced during the rinsing and cleaning of 
equipment.  
The application involves several companies and sites. Details of transport conditions e.g. time and 
temperature, of raw material and intermediate products are not always available in the application. 
Thus, the application does not include sufficient details to ensure that the cold chain is maintained at 
all times. 
8. Risk associated with the intended end use of the product 
According to the information provided by the applicant, the final intended end use of the product is 
foal nutrition. However the possibility of the product being used to feed other animals cannot be ruled 
out. According to the information provided by the applicant, the product is clearly labelled as ‘not 
suitable for human consumption’ and ‘made from bovine colostrum’. 
The final product, i.e. the freeze-dried serocolostrum and the milk powder, is presented in a flask 
(pharmaceutical grade); it must be diluted in water. The instructions for use are shown in the 
packaging box. The solution must be prepared at least one hour and 30 minutes before administration 
to the foals. In order to prepare a bottle of Colostrinov, water at room temperature (18 to 30 °C) must 
be added to the bottle up to the 1 000 mL mark followed by thorough shaking until the product is 
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completely dissolved.
12
 The feed bottle must be warmed at a maximum temperature of 37 °C in a 
water bath or administration. The reconstituted product must be stored at 4 °C and used within 
24 hours of its preparation.  
The additional risks arising from the incorporation of powdered milk by the processor and its dilution 
in water at room temperature by the farmer are not different from those derived from the use of any 
other dehydrated dairy product on the farm.   
CONCLUSIONS AND RECOMMENDATIONS 
CONCLUSIONS 
 A comprehensive list of pathogens that could be present in bovine colostrum was not provided 
by the applicant. In particular, there is a lack of information on viral pathogens.  
 As the filtration techniques used are known to remove particles of the size of bacteria, fungi 
and protozoa from liquids, it is reasonable to assume that the microfiltration process reduces 
these contaminants to a level at least equivalent to the treatment required by the legislation. 
 A similar assumption cannot be made for viruses because of their smaller size. From the 
information provided by the applicant, it cannot be concluded whether or not the 
microfiltration process reduces the relevant viral contaminants to a level at least equivalent to 
the treatment required by the legislation. 
 Certain steps of the manufacturing process13 may modify the viral load and therefore may also 
have an impact on the efficacy of the process in reducing the level of viruses. This impact 
could not be determined based on the information provided.  
 Although a detailed HACCP Plan was provided, some improvements are necessary. In 
particular, a full list of hazards should be provided and microfiltration should be identified as a 
CCP for virus reduction. In this context, the characteristics of the micro-filters should be 
clearly specified in the description of the process. The control of the filtration process and 
maintenance of the equipment are essential for the efficacy of any method based on filtration.   
 There is no information in the application on the disposal of the wastewater produced by 
rinsing and cleaning equipment that has been in contact with the colostrum. The associated 
risk cannot therefore be assessed. 
RECOMMENDATIONS 
 The efficacy of the alternative method should be validated with colostrum artificially 
contaminated with suitable test-viruses, selected according to their size and surface properties, 
and not to their thermal resistance. Only test-strains should be used for which approved 
quantitative laboratory methods available, comparable to those described for testing 
disinfectants (DVG, 2015).  
 The cold chain, as described in the application, should be maintained at all times in order to 
ensure the safety of the product. 
 Systems should be in place to ensure the safe disposal of wastewater. 
  
                                                     
12  In the section ‘Intended use of the product by the user’ of the HACCP Plan, it is stated that 1 000 mL flask of reconstituted 
Colostrinov must be administered in 4 doses, each of 250 mL. 
13  As described in paragraphs 2 and 4 of Section 3 of Annex 6 of the application which are considered confidential. 
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lactis bacteriophage during the concentration of micellar casein by tangential 0.1 μm pore size 
microfiltration. Le Lait, 74, 419–423. 
12. Godden SM, Smith S, Feirtag JM, Green LR, Wells SJ and Fetrow JP, 2003. Effect of on-farm 
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Survival of Mycobacterium paratuberculosis and preservation of immunoglobulin G in bovine 
colostrum under experimental conditions simulating pasteurization. American Journal of 
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GLOSSARY   
Filtration Separation of two or more components from a fluid stream based primarily on 
size differences (Cheryan, 1998) 
Microfiltration Filtration designed to retain particles in the ‘micron’ range, that is, suspended 
particles in the range of 0.1–5 μm (Cheryan, 1998) 
Permeate The fraction of a filtered feedstream that goes through the membrane and is 
depleted of macromolecules (Cheryan, 1998) 
Retentate The fraction of a filtered feedstream retained by the membrane and is enriched 
by the retained macromolecules and some of the permeable solutes (Cheryan, 
1998) 
Ultrafiltration Filtration designed to retain macromolecules or particles larger than about 10–
220 Å (about 0.001–0.02 μm) (Cheryan, 1998) 
ABBREVIATIONS 
ABP Animal by-product 
BIOHAZ Panel EFSA Panel on Biological Hazards 
CCP Critical Control Point 
CFU Colony-forming unit 
EFSA European Food Safety Authority 
EU European Union 
FMDV Foot-and-mouth disease virus 
HACCP Hazard Analysis and Critical Control Points 
HTST High-Temperature Short-Time 
HuNoV Human norovirus 
Ig Immunoglobulin 
PET Polyethylene terephthalate 
SMV Snow Mountain virus 
 
